CN113893244A - 一种具有抗蓝光作用的组合物 - Google Patents
一种具有抗蓝光作用的组合物 Download PDFInfo
- Publication number
- CN113893244A CN113893244A CN202111258530.2A CN202111258530A CN113893244A CN 113893244 A CN113893244 A CN 113893244A CN 202111258530 A CN202111258530 A CN 202111258530A CN 113893244 A CN113893244 A CN 113893244A
- Authority
- CN
- China
- Prior art keywords
- lutein
- composition
- copper chlorophyllin
- blue light
- sodium copper
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000000694 effects Effects 0.000 title claims abstract description 34
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 114
- 229960005375 lutein Drugs 0.000 claims abstract description 114
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 114
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 114
- 235000012680 lutein Nutrition 0.000 claims abstract description 112
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 112
- 239000001656 lutein Substances 0.000 claims abstract description 112
- 229940079841 sodium copper chlorophyllin Drugs 0.000 claims abstract description 88
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 claims abstract description 88
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 claims abstract description 87
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims abstract description 40
- 239000003094 microcapsule Substances 0.000 claims description 65
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 238000002360 preparation method Methods 0.000 claims description 27
- 239000000679 carrageenan Substances 0.000 claims description 25
- 229920001525 carrageenan Polymers 0.000 claims description 25
- 235000010418 carrageenan Nutrition 0.000 claims description 25
- 229940113118 carrageenan Drugs 0.000 claims description 25
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 229920001661 Chitosan Polymers 0.000 claims description 13
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 13
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 108010010803 Gelatin Proteins 0.000 claims description 12
- 239000008273 gelatin Substances 0.000 claims description 12
- 229920000159 gelatin Polymers 0.000 claims description 12
- 235000019322 gelatine Nutrition 0.000 claims description 12
- 235000011852 gelatine desserts Nutrition 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 229940099898 chlorophyllin Drugs 0.000 claims description 7
- 235000019805 chlorophyllin Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- KSHPUQQHKKJVIO-UHFFFAOYSA-N [Na].[Zn] Chemical compound [Na].[Zn] KSHPUQQHKKJVIO-UHFFFAOYSA-N 0.000 claims description 6
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 229940045110 chitosan Drugs 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000001795 light effect Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- UVVWIYVATLQAFM-UHFFFAOYSA-I copper;tripotassium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,13,17-trimethyl-8-(oxidomethylidene)-17,18-dihydroporphyrin-21-ide-2-carboxylate Chemical compound [K+].[K+].[K+].[Cu+2].C1=C([N-]2)C(C)=C(C([O-])=O)C2=C(CC([O-])=O)C(C(C2C)CCC([O-])=O)=NC2=CC(C(=C2C=C)C)=NC2=CC\2=NC1=C(CC)C/2=C\[O-] UVVWIYVATLQAFM-UHFFFAOYSA-I 0.000 claims 3
- 230000001815 facial effect Effects 0.000 abstract description 7
- 235000002673 Dioscorea communis Nutrition 0.000 abstract description 6
- 241000544230 Dioscorea communis Species 0.000 abstract description 6
- 208000035753 Periorbital contusion Diseases 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 5
- 230000019612 pigmentation Effects 0.000 abstract description 5
- 230000036542 oxidative stress Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 210000000887 face Anatomy 0.000 abstract description 3
- 230000008832 photodamage Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 230000009044 synergistic interaction Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 29
- 229930002875 chlorophyll Natural products 0.000 description 15
- 235000019804 chlorophyll Nutrition 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- ZIALXKMBHWELGF-UHFFFAOYSA-N [Na].[Cu] Chemical group [Na].[Cu] ZIALXKMBHWELGF-UHFFFAOYSA-N 0.000 description 7
- 210000002752 melanocyte Anatomy 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 108010025899 gelatin film Proteins 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VDNXILQBKLFION-UHFFFAOYSA-N [K].[Cu] Chemical compound [K].[Cu] VDNXILQBKLFION-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000013642 negative control Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 235000008210 xanthophylls Nutrition 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- -1 sodium copper chlorophyllin compound Chemical class 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种具有抗蓝光作用的组合物,其组成包括叶黄素和叶绿素盐,所述叶黄素与叶绿素盐的质量百分比为1~4:1。本发明组合物,通过叶黄素/叶绿素铜钠盐复配,获得优异的抗蓝光(400‑500nm)的作用,显著优于单独使用叶黄素和叶绿素铜钠盐,具有协同增效、使得所抗波段蓝移而作用于危害程度更大的短波蓝光(400‑450nm)。同时,利用该抗蓝光复配,制备成的眼贴膜、面膜等化妆品,可保护眼周、面部皮肤的蓝光损伤,减少相应部位的氧化应激、色素沉着,减少黑眼圈、细纹,且粘附性强,不易脱落,在活动时间也能方便使用。
Description
技术领域
本发明具体涉及一种具有抗蓝光作用的组合物。
背景技术
可见光约占太阳辐射的50%,其中的三分之一是自然蓝光。蓝光比UVA射线能更深地穿透皮肤,后者仅占阳光的5%。蓝光尤其是短波蓝光(400-450nm)会引发氧化应激反应,从而加速皮肤衰老并增加色素沉着,尤其是眼周的皮肤。短波蓝光还会引发DNA损伤。人眼睛周围的皮肤很薄,仅是脸颊皮肤厚度的1/4,皮脂腺与汗腺分布很少,同时也缺乏丰厚的肌肉层,更容易受到蓝光的伤害,容易出现细纹、黑眼圈等问题。
叶黄素是一种抗氧化剂,具有强大的抗氧化功能,保护眼睛及皮肤避免自由基的伤害。除此之外叶黄素更能有效过滤伤害视网膜最严重的短波蓝光,吸收紫外线后将之驱散,抑制光氧化所造成的衰退现象,保护视网膜内的黄斑部组织不受损害。研究显示叶黄素可以减低发生老年性视网膜黄斑区病变的危险率,近几年更被建议使用在预防白内障产生,保护心脏及皮肤的健康。本发明在前期通过380~500nm波长下进行全扫描发现,叶黄素吸收峰范围为440~500nm,波长460nm处时有其最大吸收峰,而短波蓝光的波长却在400-450nm,可见单独使用叶黄素有效过滤短波蓝光的波长范围窄,限制了叶黄素抗蓝光效果的发挥,因此还有待发掘扩大叶黄素抗蓝光波长范围的方法,以提高叶黄素抗短波蓝光效果,但目前还没有关于增强叶黄素抗短波蓝光作用的研究报道,更没有预防短波蓝光效果更好的叶黄素产品的问世。
发明内容
为解决上述问题,本发明提供了叶黄素联合叶绿素盐在制备具有抗蓝光作用的联合用组合物中的用途。
进一步地,所述叶黄素与叶绿素盐的质量比为1~4:1,优选2:1。
进一步地,所述叶绿素盐为叶绿素铜钠盐、叶绿素镁钠盐、叶绿素铜钾盐和/或叶绿素锌钠盐,优选叶绿素铜钠盐。
本发明还提供了一种具有抗蓝光作用的联合用药物组合物,它含有用于同时或者分别给药的叶黄素与叶绿素盐,所述叶黄素与叶绿素盐的质量比为1~4:1。
进一步地,所述叶黄素与叶绿素盐的质量比为2:1。
更进一步地,所述叶绿素盐为叶绿素铜钠盐、叶绿素镁钠盐、叶绿素铜钾盐和/或叶绿素锌钠盐,优选叶绿素铜钠盐。
本发明还提供了一种具有抗蓝光作用的组合物,其组成包括叶黄素和叶绿素盐,所述叶黄素与叶绿素盐的质量比为1~4:1。
进一步地,所述叶黄素与叶绿素盐的质量比为2:1。
进一步地,所述叶绿素盐为叶绿素铜钠盐、叶绿素镁钠盐、叶绿素铜钾盐和/或叶绿素锌钠盐,优先叶绿素铜钠盐。
更进一步地,它是以叶黄素和叶绿素盐为活性成分,加上药学上可接受的辅料制备而成的外用制剂。
更进一步地,所述外用制剂为颗粒剂、散剂、丸剂、胶囊剂或溶液剂,优选微胶囊。
更进一步地,所述微胶囊是由如下重量配比的原料制备而成:
叶黄素/叶绿素铜钠盐1~5份,明胶1~5份,卡拉胶1~5份,甘油1~3份。
更进一步地,所述微胶囊是由如下重量配比的原料制备而成:
叶黄素/叶绿素铜钠盐1份,明胶1份,卡拉胶1份,甘油1~3份。
本发明还提供了一种制备前述组合物的方法,它包括以下步骤:
(1)按照配比称取原料;
(2)取叶黄素/叶绿素铜钠盐,加入含明胶和卡拉胶的水溶液中,450r/min,40℃搅拌30min,调pH至4,再搅拌15min,加甘油,调pH至7,300r/min,4℃搅拌30min,冷冻干燥即得。
本发明还提供了一种前述组合物在制备具有抗蓝光作用的药品或护肤品中的用途。
本发明还提供了一种具有抗蓝光作用的护肤品,它是由包括如下重量配比的原料制备而成:
前述组合物1~2%、卡拉胶0.5~1%、羟甲基纤维素0.5~1%、壳聚糖0.5~1%,其余为水。
进一步地,它是由包括如下重量配比的原料制备而成:
前述组合物1.5%、卡拉胶0.5%、羟甲基纤维素0.5%、壳聚糖0.5%,其余为水。
本发明最后提供了一种制备前述护肤品的方法,它包括如下步骤:
a、按照配比称取原料;
b、取卡拉胶、羟甲基纤维素、壳聚糖和水混合,450r/min,40℃搅拌3h,再加权利要求1所述组合物搅拌1h,过滤,即得
本发明组合物,通过叶黄素/叶绿素铜钠盐复配,获得优异的抗蓝光(400-500nm)的作用,显著优于单独使用叶黄素和叶绿素铜钠盐,具有协同增效、使得所抗波段蓝移而作用于危害程度更大的短波蓝光(400-450nm)。同时,利用该抗蓝光复配,制备成的眼贴膜、面膜等化妆品,可保护眼周、面部皮肤的蓝光损伤,减少相应部位的氧化应激、色素沉着,减少黑眼圈、细纹,且粘附性强,不易脱落,在活动时间也能方便使用,具备实际推广应用价值。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1 380~500nm波长全扫描图
图2微胶囊显微图和粒径分布
图3不同条件下微胶囊稳定性
图4叶黄素/叶绿素铜钠盐微胶囊细胞毒理学
图5负载叶黄素/叶绿素铜钠盐微胶囊凝胶的实物图与扫描电镜图
图6负载叶黄素/叶绿素铜钠盐微胶囊凝胶对细胞存活率的影响
图7负载叶黄素/叶绿素铜钠盐微胶囊凝胶透皮情况
图8负载叶黄素/叶绿素铜钠盐微胶囊对蓝光诱导ROS的影响
图9负载叶黄素/叶绿素铜钠盐微胶囊凝胶对蓝光引起色素沉着的影响
图10负载叶黄素/叶绿素铜钠盐微胶囊凝胶对蓝光引起成纤维细胞老化的影响
图11负载叶黄素/叶绿素铜钠盐微胶囊凝胶使用典型效果图
具体实施方式
实施例1、本发明叶黄素/叶绿素铜钠盐微胶囊的制备
配方:叶黄素/叶绿素铜钠盐(质量比2:1)0.25g,明胶0.25g,卡拉胶0.25g,甘油0.25g。
制备方法:取明胶,卡拉胶溶解于水制成50mL溶液,加入叶黄素和叶绿素铜钠盐,450r/min,40℃搅拌30min。调节pH至4,继续搅拌15min。加入甘油,调节pH至7,300r/min,4℃搅拌30min。冷冻干燥,即得。
实施例2、本发明叶黄素/叶绿素铜钠盐微胶囊的制备
配方:叶黄素/叶绿素铜钠盐(质量比2:1)0.25g,明胶0.25g,卡拉胶0.25g,甘油0.75g。
制备方法:同实施例1
实施例3、本发明叶黄素/叶绿素铜钠盐微胶囊的制备
配方:叶黄素/叶绿素铜钠盐(质量比2:1)0.5g,明胶0.25g,卡拉胶0.25g,甘油0.3g。
制备方法:同实施例1
实施例4、本发明叶黄素/叶绿素铜钠盐微胶囊的制备
配方:叶黄素/叶绿素铜钠盐(质量比2:1)0.5g,明胶0.5g,卡拉胶0.25g,甘油0.1g。
制备方法:同实施例1
实施例5、本发明眼部凝胶贴膜的制备
配方:实施例1制备的叶黄素/叶绿素铜钠盐微胶囊1.5%、卡拉胶0.5%、羟甲基纤维素0.5%、壳聚糖0.5%,其余为去离子水;
制备方法:
a、按照配比称取原料;
b、取卡拉胶、羟甲基纤维素、壳聚糖和水混合,450r/min,40℃搅拌3h,再加入叶黄素/叶绿素铜钠盐微胶囊继续搅拌1h,半透膜过滤,即得凝胶贴膜。
实施例6、本发明眼部凝胶贴膜的制备
配方:实施例1制备的叶黄素/叶绿素铜钠盐微胶囊1%、卡拉胶0.5%、羟甲基纤维素0.5%、壳聚糖0.5%,其余为去离子水;
制备方法:同实施例5
实施例7、本发明眼部凝胶贴膜的制备
配方:实施例1制备的叶黄素/叶绿素铜钠盐微胶囊1%、卡拉胶1%、羟甲基纤维素1%、壳聚糖1%,其余为去离子水;
制备方法:同实施例5
实施例8、本发明眼部凝胶贴膜的制备
配方:实施例1制备的叶黄素/叶绿素铜钠盐微胶囊2%、卡拉胶1%、羟甲基纤维素1%、壳聚糖1%,其余为去离子水;
制备方法:同实施例5
实施例9、本发明眼部凝胶贴膜的制备
配方:实施例1制备的叶黄素/叶绿素铜钠盐微胶囊2%、卡拉胶0.5%、羟甲基纤维素0.5%、壳聚糖0.5%,其余为去离子水;
制备方法:同实施例5
以下通过试验例来说明本发明的有益效果。
试验例1本发明抗蓝光研究
1、叶黄素/叶绿素铜钠盐复配
用DMSO分别溶解叶黄素、叶绿素铜钠盐和叶黄素/叶绿素铜钠盐复配物,通过在380~500nm波长下进行全扫描,叶黄素吸收峰范围为440~500nm,波长460nm处时有其最大吸收峰;叶绿素铜钠盐最大吸收峰范围为405~420nm,波长420nm处时有其最大吸收峰;当叶黄素与叶绿素铜钠盐按照1:1至4:1配比,特别是比例为2:1的复配后,吸收峰发生了蓝移,移动至380~500nm,且在相同浓度(25μg/mL)下,吸收峰增加明显,吸收强度提高了3-10倍。详见图1。
2、叶黄素/叶绿素铜钠盐微胶囊的制备
通过筛选实验确定了制备叶黄素/叶绿素铜钠盐微胶囊的最佳条件工艺为:
0.25g明胶,0.25g卡拉胶溶解于水制备成50mL溶液,加入0.25g叶黄素和叶绿素铜钠盐,450r/min,40℃搅拌30min。调节PH至4,继续搅拌15min。加入0.25g甘油,调节pH至7,300r/min,4℃搅拌30min。冷冻干燥,即得;
制得的叶黄素/叶绿素铜钠盐微胶囊的形态特征见图2,从图2可见:微胶囊形态规则,分布均匀,粒径大小为5μm。包封率为48.21%。
3、微胶囊稳定性:
①相对湿度:将质量比2:1的叶黄素/叶绿素铜钠盐的混合物及上述制备的叶黄素/叶绿素铜钠盐微胶囊分别在不同相对湿度(30%、80%)下避光恒温保存,每隔十天测试叶黄素/叶绿素铜钠盐含量。在30%湿度相对稳定,随着湿度增加,未处理为微胶囊的叶黄素/叶绿素铜钠盐含量快速下降,而经处理后含量下降慢。
②光照:将质量比2:1的叶黄素/叶绿素铜钠盐的混合物及上述制备的叶黄素/叶绿素铜钠盐微胶囊分别置于透明瓶和棕色瓶里恒温保存,每隔十天测试叶黄素/叶绿素铜钠盐含量。在避光条件下相对稳定,光照条件下未处理为微胶囊的叶黄素/叶绿素铜钠盐含量快速下降,而经处理后含量下降慢。
③温度:将质量比2:1的叶黄素/叶绿素铜钠盐的混合物及上述制备的叶黄素/叶绿素铜钠盐微胶囊分别在不同相对温度(5℃、25℃、45℃)下避光保存,每隔十天测试叶黄素/叶绿素铜钠盐含量。在5℃条件下相对稳定,25℃条件下未处理较处理组含量下降快,45℃未处理较处理组含量进一步快速降低。具体见图3。
4.叶黄素/叶绿素铜钠盐微胶囊毒理学
在96孔板中按照4×103个/孔的密度接种角质形成细胞和黑素细胞,待细胞完全贴壁后加入不同浓度的叶黄素/叶绿素铜钠盐(质量比2:1)溶液(0、12.5、25、50、10uM)进行干预,每组有5个复孔,同时设置空白对照组(不加细胞,仅有培养基)和阴性对照组。干预24h后用排枪加入CCK-8溶液,体积为10ul/孔,37℃避光孵育1-2小时,酶标仪检测450nm处OD值。导出数据,细胞增殖率%=(OD450实验组-OD450空白对照组)/(OD450阴性对照组-OD450空白对照组)×100%上述制备的的叶黄素/叶绿素铜钠盐微胶囊浓度至100μg/mL对角质形成细胞和黑素细胞无细胞毒性,细胞存活率大于90%。详见图4。
5.制备粘附凝胶贴膜
0.5-1%卡拉胶,0.5-1%羟甲基纤维素,0.5-1%壳聚糖,450r/min,40℃搅拌3h,加入1-2%上述制备的叶黄素/叶绿素铜钠盐微胶囊继续搅拌1h,半透膜过滤制备成具备粘附力的凝胶。所制备的凝胶贴膜,具备良好的粘性,在普通活动状态下不会脱落。扫描电镜图显示表面平滑,形态良好。详见图5。
6.凝胶贴膜抗蓝光作用
①细胞存活率
分别取把角质形成细胞和黑素细胞按每孔3×105个细胞接种于6孔板中,在37℃、5%CO2培养箱中培养过夜。当细胞密度长到皿底70%时,分别用锡伯纸遮盖、100J/cm2的蓝光照射、不含叶黄素/叶绿素铜钠盐微胶囊的空白凝胶遮盖、上述制备的负载叶黄素/叶绿素铜钠盐微胶囊凝胶遮盖处理细胞,去除废液后,PBS清洗一遍,加入CCK-8溶液,体积为10ul/孔,37℃避光孵育1-2小时,酶标仪检测450nm处OD值。导出数据,计算细胞存活率。
在细胞层面上,100J/cm2的蓝光造成角质形成细胞和黑素细胞死亡50%左右,而以负载叶黄素/叶绿素铜钠盐微胶囊凝胶可以抗蓝光至细胞存活率90%左右,效果明显。详见图6。
②释放率
负叶黄素/叶绿素铜钠盐微胶囊凝胶可以在皮肤中缓慢释放,微胶囊接荧光切片观察,使用10min后药物穿过角质层,30min进入表皮层,60min穿过表皮基底层进入真皮层。详见图7。
③抗蓝光引起的自由基
分别取把角质形成细胞和黑素细胞按每孔3×104个细胞接种于24孔板中,在37℃、5%CO2培养箱中培养过夜。当细胞密度长到皿底70%时,分别用锡伯纸遮盖、100J/cm2的蓝光照射、不含叶黄素/叶绿素铜钠盐微胶囊的空白凝胶遮盖、上述制备的负载叶黄素/叶绿素铜钠盐微胶囊凝胶遮盖处理细胞,去除废液后,PBS清洗一遍,加入DCFH-DA染液,37℃避光孵育30min,PBS清洗一遍,荧光显微镜下观察拍照。
100J/cm2的蓝光造成角质形成细胞ROS增加,而以负载叶黄素/叶绿素铜钠盐微胶囊可以抗蓝光引起的ROS,效果明显。详见图8。
④抗蓝光引起的色素沉着
黑素细胞按每孔3×105个细胞接种于6孔板中,在37℃、5%CO2培养箱中培养过夜。当细胞密度长到皿底70%时,分别用锡伯纸遮盖、100J/cm2的蓝光照射、不含叶黄素/叶绿素铜钠盐微胶囊的空白凝胶遮盖、上述制备的负载叶黄素/叶绿素铜钠盐微胶囊凝胶遮盖处理细胞,去除废液后,PBS清洗一遍,用0.25%胰酶37℃消化细胞,加入含FBS的培养基终止消化,轻吹打下所有的贴壁细胞,收集到1.5mL离心管内。1000rpm离心3min收集细胞后去上清。加入1mL PBS混匀后清洗一遍,观察拍照。去除PBS后,每管加入350uL 1MNaOH溶液,80℃水浴30min至黑色素完全溶解,酶标仪检测405nm处OD值,计算黑素含量。100J/cm2的蓝光造成黑素细胞黑素含量增加,而以负载叶黄素/叶绿素铜钠盐微胶囊可以抗蓝光引起的黑素含量增加,效果明显。详见图9。
⑤抗蓝光引起的细胞老化
成纤维细胞按每孔3×105个细胞接种于6孔板中,在37℃、5%CO2培养箱中培养过夜。当细胞密度长到皿底70%时,分别用锡伯纸遮盖、100J/cm2的蓝光照射、不含叶黄素/叶绿素铜钠盐微胶囊的空白凝胶遮盖、上述制备的叶黄素/叶绿素铜钠盐微胶囊凝胶遮盖处理细胞,去除废液后,PBS清洗一遍,加入1mLβ-半乳糖苷酶染色固定液,室温固定15min。吸除细胞固定液,PBS洗涤细胞3次,每孔加入1mL染色工作液。37℃孵育过夜,parafilm膜封住6孔板防止蒸发。普通光学显微镜下观察。
100J/cm2的蓝光造成成纤维细胞β-半乳糖苷酶含量增加,代表老化产生,而以负载叶黄素/叶绿素铜钠盐微胶囊可以抗蓝光引起的老化增加,效果明显。详见图10。
7.凝胶贴膜人体功效验证
①眼贴膜对眼周问题作用
挑选60名25--40岁色素型黑眼圈女性受试者,随机分为三组,分别为空白组:不用任何眼周护理产品;对照组:使用空白胶,按实施例5制备的不含有负载叶黄素/叶绿素铜钠盐微胶囊凝胶;实验组:使用按实施例5制备的负载叶黄素/叶绿素铜钠盐微胶囊凝胶。
每天早晚各一次,每次10分钟,持续进行120天。实验时尽量降低其他因素对测试结果的影响(例如要求受试者每天睡眠时间保持8小时左右)
经试验,受试者在使用前,使用后60天和使用后120天相同环境下拍摄面部照片,经Adobe photoshop CC统一校色后,ImageJ软件获取下眼睑黑眼圈区域的CIEL*a*b*色度学空间颜色数据(CIE国际照明委员会)评价使用凝胶贴膜治疗眼周问题的疗效,结果显示负载叶黄素/叶绿素铜钠盐微胶囊凝胶对改善黑眼圈有效,且无刺激性。见图11、表1。
表1负载叶黄素/叶绿素铜钠盐微胶囊凝胶使用前后黑眼圈数据变化
主观测试:通过医师评估的方式,请医师对问题进行打分,每项最高为5分,每组取平均值,每周打分一次。
表2眼部使用负载叶黄素/叶绿素铜钠盐微胶囊凝胶前后主观测试变化
②面贴膜对面部问题作用
挑选60名35--60岁皮肤暗沉、有轻度细纹女性受试者,随机分为三组,分别为空白组:不用任何眼周护理产品;对照组:使用空白胶,实施例5制备不含有负载叶黄素/叶绿素铜钠盐微胶囊;实验组:使用实施例5制备负载叶黄素/叶绿素铜钠盐微胶囊凝胶。
主观测试:通过医师评估的方式,请医师对问题进行打分,每项最高为5分,每组取平均值,每周打分一次。
表3面部使用负载叶黄素/叶绿素铜钠盐微胶囊凝胶前后主观测试变化
从表3可见:相对不使用眼周护理品及不含叶黄素/叶绿素铜钠盐的微胶囊凝胶,本发明叶黄素/叶绿素铜钠盐微胶囊凝胶能显著改善面部暗沉、减少皱纹数量,减轻皱纹深度。
综上,本发明组合物,通过叶黄素/叶绿素铜钠盐复配,获得优异的抗蓝光(400-500nm)的作用,使得所抗波段蓝移而作用于危害程度更大的短波蓝光(400-450nm)。同时,利用该抗蓝光复配,制备成的眼贴膜、面膜等化妆品,可保护眼周、面部皮肤的蓝光损伤,减少相应部位的氧化应激、色素沉着,减少黑眼圈、细纹,且粘附性强,不易脱落,在活动时间也能方便使用,具备实际推广应用价值。
Claims (18)
1.叶黄素联合叶绿素盐在制备具有抗蓝光作用的联合用组合物中的用途。
2.根据权利要求1所述的用途,其特征在于:所述叶黄素与叶绿素盐的质量比为1~4:1,优选2:1。
3.根据权利要求1或2所述的用途,其特征在于:所述叶绿素盐为叶绿素铜钠盐、叶绿素镁钠盐、叶绿素铜钾盐和/或叶绿素锌钠盐,优选叶绿素铜钠盐。
4.一种具有抗蓝光作用的联合用组合物,其特征在于:它含有用于同时或者分别给药的叶黄素与叶绿素盐,所述叶黄素与叶绿素盐的质量比为1~4:1。
5.根据权利要求1所述的联合用组合物,其特征在于:所述叶黄素与叶绿素盐的质量比为2:1。
6.根据权利要求4或5所述的联合用药物组合物,其特征在于:所述叶绿素盐为叶绿素铜钠盐、叶绿素镁钠盐、叶绿素铜钾盐和/或叶绿素锌钠盐,优选叶绿素铜钠盐。
7.一种具有抗蓝光作用的组合物,其特征在于,其组成包括叶黄素和叶绿素盐,所述叶黄素与叶绿素盐的质量比为1~4:1。
8.根据权利要求7所述的组合物,其特征在于:所述叶黄素与叶绿素盐的质量比为2:1。
9.根据权利要求7所述的组合物,其特征在于:所述叶绿素盐为叶绿素铜钠盐、叶绿素镁钠盐、叶绿素铜钾盐和/或叶绿素锌钠盐,优选叶绿素铜钠盐。
10.根据权利要求7~9任意一项所述的组合物,其特征在于:它是以叶黄素和叶绿素盐为活性成分,加上药学上可接受的辅料制备而成的外用制剂。
11.根据权利要求10所述的组合物,其特征在于:所述外用制剂为颗粒剂、散剂、丸剂、胶囊剂或溶液剂,优选微胶囊。
12.根据权利要求11所述的组合物,其特征在于:所述微胶囊是由包括如下重量配比的原料制备而成:
叶黄素/叶绿素铜钠盐1~5份,明胶1~5份,卡拉胶1~5份,甘油1~3份。
13.根据权利要12所述的组合物,其特征在于:所述微胶囊是由包括如下重量配比的原料制备而成:
叶黄素/叶绿素铜钠盐1份,明胶1份,卡拉胶1份,甘油1~3份。
14.一种制备权利要求7~13任一项所述组合物的方法,其特征在于:它包括以下步骤:
(1)按照配比称取原料;
(2)取叶黄素/叶绿素铜钠盐,加入含明胶和卡拉胶的水溶液中,450r/min,40℃搅拌30min,调pH至4,再搅拌15min,加甘油,调pH至7,300r/min,4℃搅拌30min,冷冻干燥即得。
15.权利要求7~13任一项所述组合物在制备具有抗蓝光作用的药品或护肤品中的用途。
16.一种具有抗蓝光作用的护肤品,其特征在于:它是由包括如下重量配比的原料制备而成:
权利要求7所述组合物1~2%、卡拉胶0.5~1%、羟甲基纤维素0.5~1%、壳聚糖0.5~1%,其余为水。
17.根据权利要求7所述的护肤品,其特征在于:它是由包括如下重量配比的原料制备而成:
权利要求7所述组合物1.5%、卡拉胶0.5%、羟甲基纤维素0.5%、壳聚糖0.5%,其余为水。
18.一种制备权利要求16所述护肤品的方法,其特征在于:它包括如下步骤:
a、按照配比称取原料;
b、取卡拉胶、羟甲基纤维素、壳聚糖和水混合,450r/min,40℃搅拌3h,再加权利要求7所述组合物搅拌1h,过滤,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111258530.2A CN113893244B (zh) | 2021-10-27 | 2021-10-27 | 一种具有抗蓝光作用的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111258530.2A CN113893244B (zh) | 2021-10-27 | 2021-10-27 | 一种具有抗蓝光作用的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113893244A true CN113893244A (zh) | 2022-01-07 |
CN113893244B CN113893244B (zh) | 2023-04-21 |
Family
ID=79026499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111258530.2A Active CN113893244B (zh) | 2021-10-27 | 2021-10-27 | 一种具有抗蓝光作用的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113893244B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117085129A (zh) * | 2023-10-18 | 2023-11-21 | 山东中医药大学 | 一种光敏剂脱镁叶绿酸盐a的应用 |
CN117357459A (zh) * | 2023-11-04 | 2024-01-09 | 河北贵秋绿色生物科技有限公司 | 一种具有抗蓝光作用的胶原蛋白肽组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104327547A (zh) * | 2014-08-21 | 2015-02-04 | 金子恒 | 一种替代合成色素的天然色素组合物及其应用 |
CN108025195A (zh) * | 2015-04-08 | 2018-05-11 | 凯敏工业公司 | 叶黄素对人类皮肤细胞系抗蓝光的防护作用 |
-
2021
- 2021-10-27 CN CN202111258530.2A patent/CN113893244B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104327547A (zh) * | 2014-08-21 | 2015-02-04 | 金子恒 | 一种替代合成色素的天然色素组合物及其应用 |
CN108025195A (zh) * | 2015-04-08 | 2018-05-11 | 凯敏工业公司 | 叶黄素对人类皮肤细胞系抗蓝光的防护作用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117085129A (zh) * | 2023-10-18 | 2023-11-21 | 山东中医药大学 | 一种光敏剂脱镁叶绿酸盐a的应用 |
CN117357459A (zh) * | 2023-11-04 | 2024-01-09 | 河北贵秋绿色生物科技有限公司 | 一种具有抗蓝光作用的胶原蛋白肽组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113893244B (zh) | 2023-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113893244B (zh) | 一种具有抗蓝光作用的组合物 | |
TWI736755B (zh) | 包含植物萃取物的組成物及其減少紫外線所致皮膚損傷之用途 | |
EP1841404A1 (en) | Skin-condition improving composition comprising vaccinium uliginosum extract and method for preparation thereof | |
CN113730308B (zh) | 一种含有抗蓝光功效脂质体的眼霜组合物及其制备方法 | |
KR101617152B1 (ko) | 붉나무 미숙과 추출물을 유효성분으로 포함하는 화장료 조성물 | |
KR101824770B1 (ko) | 적하수오 부정근 추출물을 함유하는 피부 주름개선 기능성 화장료 조성물 | |
KR102593544B1 (ko) | 호장근 뿌리 추출물을 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물 | |
CN111265441A (zh) | 可增强皮肤夜间修复、再生能力的组合物及其应用 | |
CN102327200A (zh) | 一种美白祛斑产品及其制备方法 | |
CN112156143B (zh) | 一种具有抗氧化功能的复合营养素组合物 | |
CN103156843A (zh) | 一种用于美白祛斑的组合物及其制剂 | |
CN115990236B (zh) | 一种在医美术后使用的组合物及其制备方法 | |
CN112245348A (zh) | 一种护肤面霜及其制备方法 | |
KR101803757B1 (ko) | 생약재 복합 발효 추출물을 유효성분으로 함유하는 화장료 조성물 | |
CN113876626B (zh) | 一种对蓝光诱导皮肤细胞损伤具有保护作用的组合物及其在化妆品中的应用 | |
CN107753378A (zh) | 一种中草药提取液及其制备方法和应用 | |
KR20100114349A (ko) | 적포도잎 추출물, 베리 혼합물 및 셀레늄을 함유하는 항산화용 조성물 | |
KR101093901B1 (ko) | 조직배양한 금선련 추출물을 포함하는 화장료 조성물 및 상기 조직배양한 금선련 추출물의 제조방법 | |
KR102503192B1 (ko) | 흰무늬엉겅퀴씨 추출물을 유효성분으로 포함하는 하이드로겔 제형의 화장료 조성물 | |
KR20020093251A (ko) | 십장생(十長生) 관련 천연물(솔싹, 영지버섯, 알부틴,녹용, 자라, 게르마늄, 로얄제리, 홍삼, 연어알 및레몬)의 혼합추출물을 함유한 화장료 조성물 | |
CN113730330A (zh) | 一种具有祛黑眼圈功效的眼霜组合物及其制备方法 | |
KR102650192B1 (ko) | 스노우베리 과육을 포함하는 화장료 조성물 및 이의 제조방법 | |
CN112843155B (zh) | 一种适合产妇用的祛斑及缓解腰痛的组合物 | |
KR102534261B1 (ko) | 몰로키아 추출물과 민들레 및 보리 복합 추출물을 포함하는 팽창선조 예방, 개선 또는 치료용 조성물 | |
KR100965085B1 (ko) | 피부 미백용 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20220107 Assignee: Chengdu Qingshan Likang Pharmaceutical Co.,Ltd. Assignor: WEST CHINA HOSPITAL OF SICHUAN University Contract record no.: X2023980035489 Denomination of invention: A composition with anti blue light effect Granted publication date: 20230421 License type: Exclusive License Record date: 20230516 |